Skip to Content

Skin/Melanoma Trials

EA6134: DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing)
Aims: This study will test which treatment to receive first and the potential sequence of treatments for melanoma
Diagnosis: Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH17-194
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Elita Fine at 847.570.2698
Open to Enrollment: Yes

EA6141: A Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma  
Aims: The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab. 
Diagnosis:  Melanoma
Principal Investigator: Bruce Brockstein, MD
IRB Approval Number: EH16-200
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

 

UC15-1788: A Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Aims: The purpose of this research study is to determine whether pembrolizumab in combination with ipilumumab is an effective regimen for subjects who have previously received an anti-PD1 antibody such as pembrolizumab or nivolumab.
Diagnosis:  Melanoma
Principal Investigator: Bruce Brockstein, MD 
IRB Approval Number: EH17-086
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

S1320: A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
Aims: The purpose of this research study is to compare the good and bad effects of having a break in treatment with dabrafenib and trametinib comparing to continuous treatment.
Diagnosis:  Melanoma
Principal Investigator: Bruce Brockstein, MD 
IRB Approval Number: EH17-074
Sponsor: Southwest Oncology Group 
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes